EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tall Cell Carcinoma of the Breast With Reverse Polarity: Expanding the Molecular Spectrum With IDH1 R132 Mutation

Abhisek Jha iD, Shristi Gupta iD, Asmita Rayamajhi, Sajan Yadav, Kuldeep Timilsina, Pragati Gurung, Amit Kumar Sah

Clinical Case Reports · 2026-05 · 14 (5)

DOI: 10.1002/ccr3.72599 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Case Reports, online erschienen am 24.04.2026. Verfasst von Abhisek Jha und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology Birat Medical College and Teaching Hospital Morang Nepal. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tall cell carcinoma of the breast with reversed polarity (TCCRP) is a rare type of invasive breast cancer with overlapping histopathological features with papillary thyroid carcinoma and a characteristic immunohistochemical (IHC) and molecular profile. Case Presentation: A 72‐year‐old female presented with a left breast mass and purulent nipple discharge. Imaging showed a BI‐RADS 4 lesion on mammography and a heterogeneous, lobulated mass on computed tomography (CT), confined to the breast. Core biopsy suggested low‐grade invasive carcinoma. She underwent a left simple mastectomy with sentinel lymph node biopsy. Histopathology was consistent with features of TCCRP. IHC and molecular analysis revealed a hormone receptor (HR)‐positive TCCRP with IDH1 R132 mutation with low proliferative index. The patient received adjuvant radiotherapy (40 Gy/15 fractions) and is under 5‐year letrozole therapy. At 18‐month follow‐up, she remained disease‐free, with no recurrence or metastasis. This case underscores the clinical, histopathological, immunophenotypic, and molecular features of TCCRP, including the rare IDH1 R132H mutation. Timely surgical and hormonal therapy ensures excellent prognosis, and future studies on targeted IDH1/IDH2 and PIK3CA therapies may expand treatment options.

Schlagwörter

Stichwörter der Autor:innen

IDH1 R132 mutationTCCRPbreast carcinomahormonal therapyletrozolesimple mastectomy

Autor:innen und Institutionen

  • Department of Clinical Oncology Birat Medical College and Teaching Hospital Morang Nepal.

ORCID-Profile: Abhisek Jha, Shristi Gupta

Zitieren

APA

Jha, A., Gupta, S., Rayamajhi, A., Yadav, S., Timilsina, K., Gurung, P., & Sah, A. K. (2026). Tall Cell Carcinoma of the Breast With Reverse Polarity: Expanding the Molecular Spectrum With IDH1 R132 Mutation. Clinical Case Reports, 14(5). https://doi.org/10.1002/ccr3.72599

Vancouver

Jha A, Gupta S, Rayamajhi A, Yadav S, Timilsina K, Gurung P, et al. Tall Cell Carcinoma of the Breast With Reverse Polarity: Expanding the Molecular Spectrum With IDH1 R132 Mutation. Clinical Case Reports. 2026;14(5). doi:10.1002/ccr3.72599

BibTeX
@article{Jha2026,
  author = {Jha, Abhisek and Gupta, Shristi and Rayamajhi, Asmita and Yadav, Sajan and Timilsina, Kuldeep and Gurung, Pragati and Sah, Amit Kumar},
  title = {Tall Cell Carcinoma of the Breast With Reverse Polarity: Expanding the Molecular Spectrum With IDH1 R132 Mutation},
  journal = {Clinical Case Reports},
  year = {2026},
  volume = {14},
  number = {5},
  doi = {10.1002/ccr3.72599}
}
Kostenlos starten →